EUVIMEDEUVIMED entdecken
Crossref

Incidence and treatment of nasal carcinomas between 2010 and 2020

Katharina Bahr-Hamm, Nicole Orosz, Jörn Brom, Christoph Matthias, Kai Helling

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S204

DOI: 10.1055/s-0044-1784658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Katharina Bahr-Hamm und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nasal carcinomas are among the rarer tumour entities in the head and neck region, with squamous cell carcinomas being the most common. Subjectively, there has been a recent increase in cases of locally advanced nasal carcinoma requiring ablative and reconstructive therapy, which raises the question of incidence trends and possible influencing factors. A retrospective data analysis was performed on patients with nasal carcinoma who presented to the Department of Otolaryngology, University of Mainz, Germany, between 2010 and 2020. Demographic data, previous and concomitant diseases, TNM classification, histological grading, type of therapy and reconstruction were recorded. Follow-up data on local findings and recurrence-free survival were also collected and analysed. A total of 78 cases of nasal cancer were analysed. These included nine different histological entities. Squamous cell carcinoma was the largest group with 63 cases (81%). Of the squamous cell carcinomas. The mean age at diagnosis was 62 years (±12.9 years). At the time of initial diagnosis, 76.3% of cases were in early stageand 23.7% in advanced stage (III, IVA, IVB). Predominantly low-grade differentiations were found. At initial diagnosis, 96.8% of patients received surgical treatment, of which 35% had already undergone (partial) ablation. Adjuvant radiotherapy was received by 54% and radiochemotherapy by 9.5%. During the observation period, 25.4% of patients had a recurrence. Plastic reconstruction was performed in 46.1% of patients (28.6% single-stage and 17.5% multi-stage). Epithetic reconstruction was performed in 22.2% of patients. There was an increase in ablative surgical procedures over the period analysed. There was a peak in frequency towards the end of the observation period in 2019. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Bahr-Hamm, K., Orosz, N., Brom, J., Matthias, C., & Helling, K. (2024). Incidence and treatment of nasal carcinomas between 2010 and 2020. Laryngo-Rhino-Otologie, 103(S 02 S 02), S204. https://doi.org/10.1055/s-0044-1784658

Vancouver

Bahr-Hamm K, Orosz N, Brom J, Matthias C, Helling K. Incidence and treatment of nasal carcinomas between 2010 and 2020. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S204. doi:10.1055/s-0044-1784658

BibTeX
@article{BahrHamm2024,
  author = {Bahr-Hamm, Katharina and Orosz, Nicole and Brom, Jörn and Matthias, Christoph and Helling, Kai},
  title = {Incidence and treatment of nasal carcinomas between 2010 and 2020},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S204},
  doi = {10.1055/s-0044-1784658}
}
Kostenlos starten →